Prostate-specific Antigen Concentration Research Articles

Light Absorption Measurement With a CMOS Biochip for Quantitative Immunoassay Based Point-of-Care Applications.

We present a CMOS biochip-based photometer for quantitative immunoassay diagnostics. The photometer quantifies the concentration of antigens based on light absorption, which allows for a low-cost implementation without expensive optical components. We propose a light controller to lower the start-up and settling time of the light source to 30 seconds, to facilitate fast measurement starts, and to decrease the overall measurement times. The application-specific integrated circuit (ASIC) contains a 6 x 7-sensor array with 100 μm x 100 μm photodiodes that serve as signal transducers. The ASIC was developed in a normal 0.35- μm CMOS technology, avoiding the need for expensive post-CMOS processes. We present our strategy for the assembly of the ASIC and the immobilization of antibodies. For its first time, we demonstrate the quantification of prostate specific antigen (PSA) with an optoelectronic CMOS biochip using this approach. A PSA immunoassay is performed on the top surface of the CMOS sensor array, enzyme kinetics and PSA concentration are measured within 6 minutes with a limit of detection (LoD) of 0.5 ng/ml, which meets clinical testing requirements. We achieve an overall coefficient of variation (CV) of 7%, which is good compared to other point-of-care (PoC) systems.

Concentrations of canine prostate specific esterase, CPSE, at baseline are associated with the relative size of the prostate at three-year follow-up

BackgroundEnlargement of the prostate is associated with prostatic diseases in dogs, and an estimation of prostatic size is a central part in the diagnostic workup. Ultrasonography is often the method of choice, but biomarkers constitute an alternative. Canine prostate specific esterase (CPSE) shares many characteristics with human prostate specific antigen (PSA) and is related to prostate size. In men with clinical symptoms of prostatic disease, PSA concentrations are related to prostate growth. The aims of the present follow-up study were to evaluate if the concentration of CPSE is associated with future growth of the prostate, and if analysis of a panel of 16 steroids gives further information on prostatic growth. Owners of dogs included in a previous study were 3 years later contacted for a follow-up study that included an interview and a clinical examination. The prostate was examined by ultrasonography. Serum concentrations of CPSE were measured, as was a panel of steroids.ResultsOf the 79 dogs included at baseline, owners of 77 dogs (97%) were reached for an interview, and 22 were available for a follow-up examination. Six of the 79 dogs had clinical signs of prostatic disease at baseline, and eight of the remaining 73 dogs (11%) developed clinical signs between baseline and follow-up, information was lacking for two dogs. Development of clinical signs was significantly more common in dogs with a relative prostate size of ≥2.5 at baseline (n = 20) than in dogs with smaller prostates (n = 51). Serum concentrations of CPSE at baseline were not associated with the change in prostatic size between baseline and follow-up. Serum concentrations of CPSE at baseline and at follow-up were positively associated with the relative prostatic size (Srel) at follow-up. Concentrations of corticosterone (P = 0.024), and the class corticosteroids (P = 0.0035) were positively associated with the difference in Srel between baseline and follow-up.ConclusionsThe results support the use of CPSE for estimating present and future prostatic size in dogs ≥4 years, and the clinical usefulness of prostatic size for predicting development of clinical signs of prostatic disease in the dog. The association between corticosteroids and prostate growth warrants further investigation.

Ratiometric Antifouling Electrochemical Biosensors Based on Multifunctional Peptides and MXene Loaded with Au Nanoparticles and Methylene Blue.

A universal strategy for the construction of ratiometric antifouling electrochemical biosensors was developed based on multifunctional peptides and 2D nanomaterial MXene loaded with gold nanoparticles (AuNPs) and methylene blue (MB). The nanocomposite of MXene loaded with AuNPs and MB (MXene-Au-MB) exhibited excellent conductivity, where the AuNPs were able to capture biomolecules containing sulfhydryl terminus, and the MB molecules were used to generate electrochemical signal. The MXene-Au-MB was fixed on the electrode surface by Nafion, and the anchored peptide captured the electrochemical signal probe carboxyl-modified ferrocene (Fc) to construct an electrochemical biosensor. The multifunctional peptide containing the anchoring, antifouling, and recognizing sequences endowed the sensing surface not only the assaying function but also the capability to resist nonspecific adsorption from complex samples. In the biosensing system, with the increase in the target concentration, the electrochemical signal of MB remained constant, whereas the electrochemical signal of Fc gradually decreased, and the ratiometric detection strategy greatly improved the accuracy of the biosensor. In the presence of a model target prostate-specific antigen (PSA), the recognizing sequence was recognized and cleaved, and the ratiometric signal of Fc and MB indicated the concentration of PSA accurately and sensitively, with a detection range from 5 pg/mL to 10 ng/mL and a limit of detection of 0.83 pg/mL. Electrochemical biosensors based on the MXene-Au-MB and multifunctional peptides possessed high selectivity, accuracy, and sensitivity even in real complex biological samples because of the excellent antifouling ability of the peptide. More importantly, the assaying of other targets can be easily realized with a similar biosensing strategy by changing the recognition sequence of the multifunctional peptide, and the detection of thrombin (TB) has also been achieved in this work.

Acute toxicity of 4-week versus 5-week hypofractionated radiotherapy in localised prostate cancer

AbstractAim:To compare the acute radiation-induced bowel and bladder toxicities of two hypofractionated radiotherapy (HFRT) regimens in localised prostate cancer (PCa).Materials and methods:This trial consists of patients with histologically confirmed stage T1-T3aN0M0 PCa, a prostate-specific antigen concentration of 40 ng/mL or lower, and Eastern Cooperative Oncology Group performance status of 0–2. Participants were randomly assigned (1:1) to 56 Gy in 16 fractions over 4 weeks (arm A) or 70·2 Gy in 26 fractions over 5 weeks (arm B). Acute bowel and bladder toxicities were assessed using Radiation Therapy Oncology Group criteria.Results:Between June 2018 and December 2019, 40 patients were randomly assigned to treatment with 4-week (n = 20) and 5-week HFRT (n = 20). In the third month after completion of radiotherapy, the cumulative incidence of acute bowel and bladder toxicities of arms A and B was 20 versus 5% and 70 versus 85%, respectively. The cumulative incidence of grade 2 or worse bowel and bladder toxicities of the 5-week regimen was non-inferior to 4-week HFRT [bowel toxicity: 5% (arm A) versus 5% (arm B), bladder toxicity: 50% (arm A) versus 60% (arm B), p = 0·52).Findings:The 5-week regimen of HFRT is non-inferior to 4-week HFRT in terms of acute bowel and bladder toxicities.

A Complete Analytical Model for MOS-HEMT Biosensors: Capturing the Effect of Stern Layer and Charge Screening on Sensor Performance

This letter presents analytical and technology computer aided design models for analyzing the performance of biohigh-electron-mobility transistor (HEMT) sensors. Unlike existing models for these sensors in the literature, where the biolayer is modeled as semiconductor or insulator layer with analyte-induced interface charge (i.e., surface potential), the model presented in this letter provides a better design insights by taking into consideration charge screening effect and impact of electric double layer (Stern layer) on device performance. The simulation case study is focused on prostate cancer detection using prostate-specific antigen (PSA) present in human serum as the target biomarker. Application specific validation of the model has been presented through demonstration of a MOS-HEMT PSA sensor design with sensitivity large enough to detect clinically relevant concentration of PSA in human serum (1ng/ml-4ng/ml).

Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison

PurposeTo investigate the diagnostic performance of Prostate Imaging-Reporting and Data System version 2.0 (PI-RADSv2.0) for differentiating clinically significant prostate cancer (csPCa) from benign prostate disease on prebiopsy multiparametric MRI stratified by total prostate specific antigen (PSA) concentration. Materials and methods150 patients who had prebiopsy mpMRI, serum PSA concentration and subsequent biopsy were retrospectively analyzed. Patients were stratified by PSA concentration (Group1 ≥ 10 ng/mL; Group2 4.0–<10 ng/mL). MRI findings were assessed using PI-RADSv2.0 by two blinded radiologists. Lesions were graded histopathologically using the International Society of Urological Pathology (ISUP) score. Diagnostic performance of PI-RADSv2.0 was evaluated and compared to PSA and PSA Density (PSAD). The performance of the radiologists was compared including inter-observer agreement for PI-RADSv2.0. The correlation between imaging and histopathological biopsy results was analyzed. ResultsThe differences in total PSA, free/total PSA ratio and PSAD between benign (n = 78) and malignant (n = 72) groups were significant (p < 0.05). The PI-RADSv2.0 scores of the radiologists were strongly correlated (r = 0.912, p < 0.001) with excellent agreement, κ = 0.97 (95%CI: 0.90–1.03; p < 0.005). Receiver operating characteristics curve analysis showed significantly high predictive power for PI-RADSv2.0, total PSA and PSAD alone. Comparison of age, prostate volume, PSAD, free/total PSA ratio and total PSA values between ISUP1 and ISUP ≥ 2 cases revealed significantly increased PSAD (p < 0.001) and total PSA (p = 0.001) in the ISUP ≥ 2 group. ConclusionPI-RADSv2.0 had high diagnostic accuracy in both PSA groups. PI-RADSv2.0, PSAD and total PSA alone had significant high predictive power to detect csPCa. However, the combination of PI-RADSv2.0 and PSAD or total PSA for each reader showed no statistically significant improvement when compared to PI-RADSv2.0 alone.

Au\u2013Ag assembled on silica nanoprobes for visual semiquantitative detection of prostate-specific antigen

BackgroundBlood prostate-specific antigen (PSA) levels are widely used as diagnostic biomarkers for prostate cancer. Lateral-flow immunoassay (LFIA)-based PSA detection can overcome the limitations associated with other methods. LFIAbased PSA detection in clinical samples enables prognosis and early diagnosis owing to the use of high-performance signal reporters.ResultsHere, a semiquantitative LFIA platform for PSA detection in blood was developed using Au–Ag nanoparticles (NPs) assembled on silica NPs (SiO2@Au–Ag NPs) that served as signal reporters. Synthesized SiO2@Au–Ag NPs exhibited a high absorbance at a wide wavelength range (400–800 nm), with a high scattering on nitrocellulose membrane test strips. In LFIA, the color intensity of the test line on the test strip differed depending on the PSA concentration (0.30–10.00 ng/mL), and bands for the test line on the test strip could be used as a standard. When clinical samples were assessed using this LFIA, a visual test line with particular color intensity observed on the test strip enabled the early diagnosis and prognosis of patients with prostate cancer based on PSA detection. In addition, the relative standard deviation of reproducibility was 1.41%, indicating high reproducibility, and the signal reporter showed good stability for 10 days.ConclusionThese characteristics of the signal reporter demonstrated the reliability of the LFIA platform for PSA detection, suggesting potential applications in clinical sample analysis.

Association between serum prostate-specific antigen concentrations and the risk of developing type2 diabetes mellitus in Chinese men: A cohort study.

Aims/IntroductionThe current literature suggests that men with diabetes have a lower prostate‐specific antigen concentration than men without diabetes, but the causal association remains unclear. We aimed to investigate the association between serum prostate‐specific antigen concentrations and the risk of type 2 diabetes mellitus in a cohort study of a Chinese population.Materials and MethodsWe designed a cohort study that comprised 16,811 initially non‐diabetic Chinese men who received annual health checkups between 2009 and 2016. The outcome of this study was type 2 diabetes mellitus, identified by medical diagnosis, self‐reportage, medication use, fasting glucose, 2‐h post oral glucose or glycated hemoglobin measurements. Cox proportional hazards models were carried out to evaluate the association.ResultsDuring a median follow‐up period of 3.8 years (interquartile range 1.91–5.73 years), 1,260 participants developed incident type 2 diabetes mellitus. The multivariable model, adjusted for various potential confounders, showed that serum prostate‐specific antigen concentrations were inversely related to type 2 diabetes mellitus risk (P for trend = 0.014). Compared with the lowest quartile of serum prostate‐specific antigen, the hazard ratio and 95% confidence intervals of type 2 diabetes mellitus risk for quartile 2–4 were 0.84 (0.66–1.07), 0.75 (0.59–0.94) and 0.77 (0.62–0.96), respectively. Subgroup analyses suggested the inverse relationship was more prominent in overweight or obese participants (P for interaction = 0.013).ConclusionsHigh serum prostate‐specific antigen concentration was associated with a low risk of type 2 diabetes mellitus in Chinese men. Future studies are required to confirm these findings and investigate underlying mechanisms.

Radiomics Analysis for 177Lu-DOTAGA-(l-y)fk(Sub-KuE) Targeted Radioligand Therapy Dosimetry in Metastatic Prostate Cancer-A Model Based on Clinical Example.

177Lu-DOTAGA-(l-y)fk(Sub-KuE) a.k.a. 177Lu-PSMA I&T is currently used for radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) in several centers in Europe. Background: Dosimetry is mandatory according to EU guidelines, although routine methods for dosimetry, i.e., absorbed radiation dose calculations for radiopharmaceuticals, are missing. Methods: We created a model of dosimetric analysis utilizing voxel-based dosimetry and intra-lesion radiomics to assess their practicality in routine dosimetry. Results: As an example for the model, our patient with mCRPC had excellent therapy response; quantitatively more than 97% of the metastatic tumor burden in local and distant lymph nodes and skeleton was destroyed by four cycles of RLT. The absorbed radiation doses in metastases decreased towards later cycles of RLT. Besides the change of prostate-specific membrane antigen (PSMA) concentration and absorbed doses in the tumor, further response to RLT could be predicted from biomarker changes, such as LDH and PSA. Conclusions: Individual dosimetry is needed to understand large variations in tumor doses and mixed responses; for that purpose, routine tools should be developed. The Dosimetry Research Tool (DRT) fluently performed automated organ delineation and absorbed radiation dose calculations in normal organs, and the results in our patient were in good concordance with the published studies on 177Lu-PSMA dosimetry. At the same time, we experienced considerable challenges in voxel-based dosimetry of tumor lesions. Measurements of 177Lu-PSMA activity concentrations instead of absorbed radiation dose calculations could make routine dosimetry more flexible. The first cycle of RLT seems to have quantitatively the biggest impact on the therapy effect. Radiomics analyses could probably aid in the treatment optimization, but it should be tested in large patient populations.

Profiling the proteoforms of urinary prostate-specific antigen by capillary electrophoresis – mass spectrometry

Early detection of prostate cancer may lead to the overdiagnosis and overtreatment of patients as well as missing significant cancers. The current diagnostic approach uses elevated serum concentrations of prostate-specific antigen (PSA) as an indicator of risk. However, this test has been widely criticized as it shows poor specificity and sensitivity. In order to improve early detection and diagnosis, several studies have investigated whether different PSA proteoforms are correlated to prostate cancer. Until now, studies and methodologies for the comprehensive characterization of PSA proteoforms from biofluids are scarce. For this purpose, we developed an intact protein assay to analyze PSA by capillary electrophoresis-electrospray ionization-mass spectrometry after affinity purification from patients' urine. Here, we determined six proteolytic cleavage variants. In regard to glycosylation, tri-, di-, mono- and non-sialylated complex-type N-glycans were found on non-cleaved PSA, as well as the non-glycosylated variant. The performance of the intact protein assay was assessed using a pooled sample, obtaining an inter-day variability of 15%. Furthermore, urinary patient samples were analyzed by intact protein analysis and a bottom-up approach (glycopeptide analysis). This combined approach revealed complimentary information on both levels, demonstrating the benefit of using two orthogonal techniques to provide a thorough profile of urinary PSA. SignificanceThe detection of clinically relevant prostate cancer requires a more specific and sensitive biomarker and, in this case, several PSA proteoforms may be able to aid or improve the current PSA test. However, a comprehensive analysis of the intact PSA proteoform profile is still lacking. This study investigated the PSA proteoforms present in urine and, in particular, determined the relative contribution of cleaved PSA and non-cleaved PSA forms to the total glycosylation profile. Importantly, intact protein analysis did not require further sample treatment before being measured by CE-ESI-MS. Furthermore, its glycosylation was also assessed in a bottom-up approach to provide complementary information. Overall, these results represent an important basis for future characterization and biomarker studies.

Age-adjusted reference values for prostate-specific antigen in a multi-ethnic population.

To establish age-adjusted reference values for prostate-specific antigen in an ethnically diverse population. Between 2009 and 2017, data were collected from all men aged 40-79years, who had a prostate-specific antigen test in the northern region of New Zealand, where the prostate-specific antigen testing service is provided by a single community laboratory and using the same assay analyzer. Men known to have prostate cancer, who developed prostate cancer during the study period, who were treated with finasteride, or who had prostate-specific antigen levels above 20ng/mL were excluded. Age-adjusted prostate-specific antigen reference values were calculated for each of the main ethnic groups in the country including: Māori (indigenous), Pacific, Asian and European. For every 5-year age interval, the 95th percentile of the log prostate-specific antigen distribution was used to define the upper limit of normal. The study cohort included 215132 apparently healthy men, with a median age and prostate-specific antigen concentration of 59years and 0.9ng/mL, respectively. Prostate-specific antigen levels for the entire cohort increased with age (Pearson correlation=0.362, P<0.001). This relationship was most prominent in Pacific men. Similarly, the upper reference limit for the entire cohort increased with age, from 1.60ng/mL for men aged 40-44years to 7.61ng/mL for those aged 75-79years. Significant ethnic differences were present within each interval, which was most apparent in the older age groups. Ethnic differences in age-adjusted prostate-specific antigen reference values are present in New Zealand. These need to be considered when prostate-specific antigen results are being interpreted in clinical practice.

The electrochemical immunosensor for detection of prostatic specific antigen using quince seed mucilage-GNPs-SNPs as a green composite

Prostatic specific antigen (PSA) is known as a biomarker of prostate cancer. In males, prostate cancer is ranked second as leading cause of death out of more than 200 different cancer types1. As a result, early detection of cancer can cause a significant reduction in mortality. PSA concentration directly is related to prostate cancer, so normal serum concentrations in healthy means are 4 ng and above 10 ng as abnormal concentration. Therefore, PSA determination is important to cancer progression. In this study, a free label electrochemical immunosensor was prepared based on a new green platform for the quantitative detection of the PSA. The used platform was formed from quince seed mucilage containing green gold and silver nanoparticles and synthesized by the green method (using Calendula officinalis L. extract). The quince mucilage biopolymer was used as a sub layer to assemble nanoparticles and increase the electrochemical performance. This nanocomposite was used to increase the antibody loading and accelerate the electron transfer, which can increase the biosensor sensitivity. The antibodies of the PSA biomarker were successfully incubated on the green platform. Under the optimal conditions, the electrochemical impedance spectroscopy (EIS) was proportional to the PSA biomarker concentration from 0.1 pg mL−1 to 100 ng mL−1 with low limit of detection (0.078 pg mL−1). The proposed green immunosensor exhibited high stability and reproducibility, which can be used for the quantitative assay of the PSA biomarker in clinical analyses. The results of real sample analysis presented another tool for the PSA biomarker detection in physiologic models.

Association of Total Dietary Intake of Sugars with Prostate-Specific Antigen (PSA) Concentrations: Evidence from the National Health and Nutrition Examination Survey (NHANES), 2003-2010.

Background There is increasing evidence that dietary intake of sugars may be a risk factor for prostate cancer (PCa) and elevate the concentration of serum prostate-specific antigen (PSA). However, there is limited evidence of the correlation between total dietary intake of sugars and serum PSA concentrations for adult American males. Herein, we evaluated the association between total dietary intake of sugars and serum PSA concentrations in men without a malignant tumor diagnosis in the United States (US) National Health and Nutrition Examination Survey (NHANES) database. Material and Methods. In this secondary data analysis, a total of 6,403 men aged ≥40 years and without malignant tumor history were included from 2003 to 2010. The independent variable of this study was the total dietary intake of sugars, and the dependent variable was serum PSA concentrations. Covariates included dietary, comorbidity, physical examination, and demographic data. Results The average age of participants included in this study was 58.1 years (±13.6). After adjusting for the dietary, comorbidity, physical examination, and demographic data, we observed that a dietary intake increase of one gram of total dietary intake of sugars was associated with an increase of serum PSA concentrations by 0.003 ng/mL (after log2 transformed, 95% CI: 0.001 to 0.005) with a P value for trend less than 0.05. Sensitivity analysis using the generalized additive model (GAM) supported the linear association between total dietary intake of sugars and serum PSA concentrations. Conclusion The total dietary intake of sugars is independently and positively associated with serum PSA concentrations in adult American males who are without a personal history of malignant tumors.

Photoselective sharp enucleation of the prostate with a front-firing 532-nm laser: an innovative surgical technique for benign prostatic hyperplasia-a single-center study of 475 cases.

To describe the novel technique of photoselective sharp enucleation of the prostate (PSEP) with a front-firing 532-nm laser and evaluate its efficacy and safety. A seven-step standardized surgical procedure was established, and PSEP was performed in an en bloc or lobulate manner according to the size of the middle lobe of the prostate. The following clinical data of 583 patients who underwent PSEP in our center from November 2016 to May 2018 were retrospectively reviewed: maximum flow rate (Qmax), International Prostate Symptom Score (IPSS), quality of life score (Qols), post-void residual volume (PVR), prostate volume, operation time, serum prostate-specific antigen (PSA) concentration, and complications at 1, 6, and 12months postoperatively. Of the 583 patients, 475 had complete clinical information and were included in the study. The median operation time was 39min. There were significant improvements in the Qmax, IPSS, Qols, PVR and PSA concentration at each follow-up time point postoperatively. Postoperative hemorrhage occurred in 22 patients (4.6%), urinary retention in 29 (6.1%), urinary tract infection in 55 (11.6%), bladder neck contracture in 8 (1.7%), urethral strictures in 11 (2.3%), and stress urinary incontinence in 9 (1.9%). PSEP is effective and safe for the treatment of benign prostatic hyperplasia. The innovative technique integrates the excellent hemostatic property of the 532-nm laser and the high efficiency of enucleation. It decreases the occurrence of postoperative incontinence associated with "blunt" enucleation of 532-nm laser and eliminates the lack of tissue samples problem associated with photoselective vaporization of the prostate.

A label-free fluorescent aptasensor based on HCR and G-quadruplex DNAzymes for the detection of prostate-specific antigen.

Prostate specific antigen (PSA) has been considered as the most potential serological biomarker for the early stage detection of prostate cancer. Here, a label-free fluorescence aptasensing strategy for detecting PSA based on hybridization chain reaction (HCR) and G-quadruplex DNAzymes has been developed. This designed strategy consists of three DNA probes, aptamer probe (AP), hairpin probe 1 (H1) and hairpin probe 2 (H2). In the presence of target PSA, the aptamer sequences in AP specifically recognized PSA to form a PSA-aptamer complex, causing an AP conformation change and thus releasing the initiator, which triggered the chain-like assembly of H1 and H2 that yielded extended nicked double-stranded DNA through HCR. Upon the addition of hemin, the G-rich segments at the end of H1 and H2 self-assembled into the peroxidase-mimicking hemin/G-quadruplex DNAzymes, which catalyzed the hydrogen peroxide-mediated oxidation of thiamine to give a fluorescence signal dependent on the concentration of PSA. Under optimal conditions, a limit of detection of 0.05 nM and a linear range from 0.1 nM to 1 nM (R2 = 0.9942) were achieved by this assay. In addition, other interfering proteins, such as IgG, AFP and CEA, did not produce any significant change in the fluorescence intensity response, indicating good selectivity of this sensor for PSA detection. Finally, this proposed aptasensor was successfully used for diluted serum samples.

Relationship with Metalloproteinase 13, E-cadherin, Homocysteine and Co Factors Folic Acid and Vitamin B12 in Patients Diagnosed with Prostate Cancer

Introduction:: Prostate cancer (Pc) is the most frequent neoplasia in men and the second cause of death in Brazil. Objective:: To analyze the interactions and biologicals responses of Pc oxidative stress and prostatespecific antigen (PSA), E-cadherin and MMP-13. Demonstrate whether the increase of the amount of the form of E-cadherin found in the plasma of Pc patients, correlates with decrease of the PSA. Methods:: Samples were obtained through peripheral venipuncture to analyse parameters of biomarkers pc as PSA, E-cadherin, MMP-13, Homocysteine, Folic acid, Vitamin B12, Testosterone T and free following the patients diagnosis, 3 and 6 months during their treatment to analyze the biological responses of Pc oxidative stress. Results:: The analysis was performed by using immunoenzymatic assay. Statistical data processed through Excel in Windows Vista and analyzed through the Shapiro-wilk Test, ANOVA, and Spearman Test. An increase in the concentration of E-cadherin (p = 0.02), as a decrease in concentration of PSA (p &lt; 0.001), total testosterone (p &lt; 0.001) and free testosterone (p = 0.02) was observed during the treatment period without significant alterations in the remaining markers for either of the periods. Discussion:: It was found that during treatment of men diagnosed with pc that there was an an increase in the concentration of plasmatic E-cadherin, which was negatively correlated with the concentrations of folic acid (-0,03 (0,87) rs (p). It was observed that the levels of hcy are positively correlated with concentrations of total testosterone and a negative correlation. Vitamins B12 remained within the parameters of normality during the entire study. Conclusion:: P.S.A levels were free and total testosterone levels decreased. In this way, monitoring the folic acid, E-cadherin dosages of patients during the treatment phases can effectively complement in the face of remission, since it would be a way of preventing abnormal cell replications, with a clinical view prudent so that the cell methylation cycle is not affected.

Gold Nanomaterial Hybrid on PEGylated Metal Oxide Interdigitated Mini-electrode Surface to Diagnose Prostate Cancer

Prostate cancer is a leading health burden, the third most common cancer in a man. High accuracy detection and screening methods with a suitable biomarker can significantly reduce the risk of mortality. Prostate specific antigen (PSA) is the efficient and acceptable biomarker due to its level of increment in the biological fluid with the prostate cancer patient. This research was focused to establish a sensitive method of PSA detection by using gold nanoparticle (GNP) conjugated PSA specific aptamer on interdigitated mini-electrode. GNP allowed to capture higher number of aptamers on the surface and enhanced the interaction of PSA. This good detection method can determine PSA at 45[Formula: see text]aM with the sensitivity of 30[Formula: see text]aM. A linear range was noticed from 60 until 2000 aM on the regression curve at [Formula: see text]; [Formula: see text]. Moreover, spiking PSA in human serum enhances the current response with increasing PSA concentrations. This method of determination helps to quantify the PSA level and diagnose the prostate cancer at different stages.

Conducting polymer applied in a label-free electrochemical immunosensor for the detection prostate-specific antigen using its redox response as an analytical signal

A label-free electrochemical inmunosensor based on specific antibody immobilization was developed attached to an aminophenylboronic/poly-indole-6-carboxylic acid-modified electrode (APBA/6-PICA/GCE) for detection of the cancer biomarker, prostate-specific antigen (PSA). The optimal conditions for developing a reproducible bioplatform with excellent stability were determined, focusing on time and incubation temperature. Guided antibody immobilization was carried out using APBA and shown to improve the antigen-antibody affinity. Following the intrinsic redox response of 6-PICA, which corresponds to the electrode doping-undoping charge transfer process, this was chosen as an analytical electrochemical signal using square wave voltammetry (SWV). Cyclic voltammetry, electrochemical impedance spectroscopy and SWV were used in the characterization in the step-by-step optimal construction of the immunosensor and PSA detection. The calibration curve shows a linear range between 0.50 and 100.0 ng·mL −1 , with a limit of detection (LOD) of 0.11 ng·mL −1 , and a limit of quantification (LOQ) of 0.33 ng·mL −1 , respectively. Also, an affinity constant (Ka) between specific monoclonal antibody and PSA was determined at 6.37·10 9 M −1 . These analytical quality parameters propose that the bioplatform can be used to detect PSA concentrations within clinically relevant levels.

The Estimation of prostate specific antigen (PSA) concentrations in patients with prostatitis by fully automated ELISA technique.

The Aim of this study was to determine Immunogenetic expression of Toll-like receptor gene clusters related to prostatitis, to give acknowledge about Role of TLR in prostatitis immunity in men from Basrah and Maysan provinces. A case–control study included 135 confirmed prostatitis patients And 50 persons as a control group. Data about age, marital status, working, infertility, family history and personal information like (Infection, Allergy, Steroid therapy, Residency, Smoking, Alcohol Drinking, Blood group, Body max index (BMI) and the clinical finding for all patients of Prostatitis were collected. This study shows the effect of PSA level in patients with prostatitis and control group, with P-value &lt;0.0001 therefore the study shows a positive significant between elevated PSA levels and Prostatitis.

Initial Study of Thin-Film Derived Gold Nanoparticles (Au NPs) Surface Plasmon Resonance (SPR) Based Prostate-Specific Antigen (PSA) Detection

The gold nanoparticles (Au NPs) localized surface plasmon resonance (LSPR) based detection of prostate-specific antigen (PSA) biomarker was carried out in this work. Au NPs on Si and quartz substrates were synthesized by DC magnetron sputtering method followed by conventional annealing protocol. The functionalization of antibody and PSA with Au NPs was evaluated using a simple drop-cost method. The SPR peak intensity was found to be proportional to the PSA concentration. The redshift in SPR peak position might be owing to the change in refractive index around the Au NPs with the conjugation of antibody and further additional binding of specific PSA at different concentrations.